AMYLOID NEUROPATHIES

Clinical trials for AMYLOID NEUROPATHIES explained in plain language.

Never miss a new study

Get alerted when new AMYLOID NEUROPATHIES trials appear

Sign up with your email to follow new studies for AMYLOID NEUROPATHIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

One-Shot gene therapy aims to halt rare, devastating nerve disease

Disease control Ongoing

This Phase 3 trial is testing whether a single dose of an experimental gene therapy called NTLA-2001 can safely slow or stop the progression of hereditary amyloidosis with polyneuropathy (ATTRv-PN), a rare genetic disease that damages nerves. About 50 participants worldwide will …

Matched conditions: AMYLOID NEUROPATHIES

Phase: PHASE3 • Sponsor: Intellia Therapeutics • Aim: Disease control

Last updated Mar 31, 2026 12:12 UTC

AMYLOID NEUROPATHIES

Get alerted when new AMYLOID NEUROPATHIES trials appear

One-Shot gene therapy aims to halt rare, devastating nerve disease